论文部分内容阅读
在口服避孕药(OC)领域中主要研究目标之一是减少激素含量使其对代谢影响减到最小程度。本研究目的是测定雌激素对血凝系统的影响是否因复方制剂中同时使用的孕激素而减小。作者研究了两种三相制剂,新SHD415G制剂含乙炔雌二醇(EE)与新的孕激素——孕二烯酮(gestodene)和含EE及左旋18-甲炔诺酮制剂(trionetta),两种制剂中雌激素含量相同。共有23例健康妇女自愿希望使用OC,研究期间4例中止,19例完成。受试者均符合服用OC的要求,做常规检查,包括血压和仔细的妇科检查。在1、3和6个月后随访。9例服用新SHD415G制剂,10例服用trio-
One of the main research goals in the field of oral contraceptives (OCs) is to reduce hormone levels to minimize their effects on metabolism. The purpose of this study was to determine whether the effect of estrogen on the coagulation system was reduced by the concurrent use of progestin in the combination. The authors studied two three-phase formulations, the new SHD415G formulation containing ethinyl estradiol (EE) with new gestodene and EE and levonorgestrel-containing trionetta, Estrogen content was the same in both preparations. A total of 23 healthy women volunteered to use OC, with 4 discontinued during the study and 19 completed. Subjects met the requirements of taking OC, do routine examination, including blood pressure and careful gynecological examination. Follow-up after 1, 3 and 6 months. 9 patients taking the new SHD415G preparations, 10 patients taking trio-